Case Description—An 8-year-old castrated male mixed-breed dog (dog 1) and a 13-year-old spayed female mixed-breed dog (dog 2) were evaluated because of spontaneous pneumothorax.
Clinical Findings—Both dogs had decreased bronchovesicular sounds with coughing, tachypnea, cyanosis, lethargy, or a combination of these clinical signs. Radiographic examination revealed pneumothorax in both dogs and consolidation of a lung lobe in dog 2. Pneumothorax was alleviated following thoracocentesis in both dogs but recurred.
Treatment and Outcome—Dog 1 was initially treated by placement of a thoracostomy tube but underwent thoracotomy when pneumothorax recurred after tube removal; left caudal lung lobectomy was performed because a ruptured bulla was suspected, and a pulmonary bulla was histologically confirmed. Dog 2 underwent thoracotomy with left caudal lung lobectomy and partial removal of the left cranial lung lobe; diffuse pulmonary emphysema was diagnosed. This dog underwent a second surgery for right caudal lung lobectomy because of torsion. When pneumothorax recurred and additional surgery was not considered feasible, pleural access ports were placed in both dogs for repeated removal of air from the thoracic cavity. Ports were used clinically for 17 days in dog 1 and 14 days in dog 2. Dog 1 successfully underwent another surgery when pneumothorax recurred 18 days after port placement but was euthanized 17 months later when dyspnea and tachypnea recurred. Pneumothorax had not recurred further in dog 2 twenty-three months after port placement.
Clinical Relevance—Findings suggested that pleural access ports may have a role in the management of spontaneous pneumothorax in dogs.
Objective—To evaluate long-term function of vascular access ports (VAPs) implanted in the femoral vein of dogs and cats undergoing cancer treatment.
Design—Prospective clinical study.
Animals—3 dogs and 6 cats treated via chemotherapy or radiation.
Procedures—VAPs were surgically implanted in the left femoral vein of 3 dogs and 6 cats over a 1-year period. Injection port location was alternated to either a caudal thoracic or ilial location in each patient. Duration of VAP function, ease of infusion, and ease of aspiration through the VAPs were recorded, and associated complications were assessed at each VAP use. Client satisfaction with VAP placement was evaluated by use of a questionnaire.
Results—Primary uses of the VAPs included blood sampling and delivering sedative or chemotherapeutic drugs. Median duration of successful infusion was 147 days (range, 60 to 370 days), and median duration of successful aspiration was 117 days (range, 10 to 271 days). The frequency of signs of VAP-related discomfort was low (7% of patient observations). Clients were satisfied with their decision to use VAPs. Complications included partial (n = 7) or complete (2) VAP occlusion, port migration (1), and presumptive infection (1).
Conclusions and Clinical Relevance—Results suggested that VAP implantation into the femoral vein provides an acceptable means of chronic venous access in dogs and cats undergoing cancer treatment.
Objective—To determine the prognostic factors for
survival and tumor recurrence in dogs with cutaneous
mast cell tumors (MCTs) in the perineal and inguinal
regions treated surgically with or without adjunctive
radiation therapy, chemotherapy, or both.
Procedure—Medical records of dogs with histologically
confirmed MCTs in the perineal region, inguinal
region, or both treated surgically with or without
adjunctive radiation therapy, chemotherapy, or both
Results—Mean tumor-free interval was 1,635 days
(median not reached), and 1- and 2-year tumor-free
rates were 79% and 71%, respectively. Median survival
time was 1,111 days (mean, 1,223 days), and 1-
and 2-year survival rates were 79% and 61%, respectively.
Factors that negatively influenced survival time
were age at diagnosis, tumor recurrence, and treatment
Conclusions and Clinical Relevance—Results indicated
that dogs with MCTs in the inguinal and perineal
regions, if appropriately treated, may have survival
times and tumor-free intervals similar to dogs
with MCTs in other locations. ( J Am Vet Med Assoc